NASDAQ:NKTX

Nkarta Competitors

$35.78
+1.87 (+5.51 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.56
Now: $35.78
$36.35
50-Day Range
$31.25
MA: $38.18
$49.00
52-Week Range
$22.46
Now: $35.78
$79.16
Volume161,674 shs
Average Volume243,177 shs
Market Capitalization$1.17 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Nkarta (NASDAQ:NKTX) Vs. BHVN, SAGE, HCM, IMAB, ARNA, and AGIO

Should you be buying NKTX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Nkarta, including Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Hutchison China MediTech (HCM), I-Mab (IMAB), Arena Pharmaceuticals (ARNA), and Agios Pharmaceuticals (AGIO).

Nkarta (NASDAQ:NKTX) and Biohaven Pharmaceutical (NYSE:BHVN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Biohaven Pharmaceutical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/AN/AN/AN/A
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-6.89

Profitability

This table compares Nkarta and Biohaven Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NkartaN/AN/AN/A
Biohaven PharmaceuticalN/A-1,091.41%-120.85%

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Biohaven Pharmaceutical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nkarta00503.00
Biohaven Pharmaceutical021002.83

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Biohaven Pharmaceutical has a consensus price target of $96.7273, suggesting a potential upside of 28.61%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts plainly believe Nkarta is more favorable than Biohaven Pharmaceutical.

Summary

Nkarta beats Biohaven Pharmaceutical on 4 of the 7 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Sage Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/AN/AN/AN/A
Sage Therapeutics$6.87 million634.98$-680,240,000.00($13.38)-5.58

Nkarta has higher earnings, but lower revenue than Sage Therapeutics.

Profitability

This table compares Nkarta and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NkartaN/AN/AN/A
Sage Therapeutics-7,706.84%-63.81%-56.64%

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. 4.8% of Sage Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Sage Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nkarta00503.00
Sage Therapeutics08802.50

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Sage Therapeutics has a consensus price target of $86.6875, suggesting a potential upside of 16.02%. Given Nkarta's stronger consensus rating and higher possible upside, research analysts plainly believe Nkarta is more favorable than Sage Therapeutics.

Summary

Nkarta beats Sage Therapeutics on 6 of the 9 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Hutchison China MediTech (NASDAQ:HCM) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Hutchison China MediTech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/AN/AN/AN/A
Hutchison China MediTech$204.89 million21.14$-106,020,000.00($0.80)-37.19

Nkarta has higher earnings, but lower revenue than Hutchison China MediTech.

Profitability

This table compares Nkarta and Hutchison China MediTech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NkartaN/AN/AN/A
Hutchison China MediTechN/AN/AN/A

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 33.5% of Hutchison China MediTech shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Hutchison China MediTech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nkarta00503.00
Hutchison China MediTech00203.00

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Hutchison China MediTech has a consensus price target of $40.00, suggesting a potential upside of 34.45%. Given Nkarta's higher possible upside, research analysts plainly believe Nkarta is more favorable than Hutchison China MediTech.

Summary

Nkarta beats Hutchison China MediTech on 3 of the 4 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and I-Mab (NASDAQ:IMAB) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and I-Mab's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/AN/AN/AN/A
I-Mab$4.31 million975.21$-208,560,000.00($28.90)-2.02

Nkarta has higher earnings, but lower revenue than I-Mab.

Profitability

This table compares Nkarta and I-Mab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NkartaN/AN/AN/A
I-MabN/AN/AN/A

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 16.6% of I-Mab shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and I-Mab, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nkarta00503.00
I-Mab00403.00

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. I-Mab has a consensus price target of $70.00, suggesting a potential upside of 19.82%. Given Nkarta's higher possible upside, research analysts plainly believe Nkarta is more favorable than I-Mab.

Summary

Nkarta beats I-Mab on 3 of the 4 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Nkarta and Arena Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/AN/AN/AN/A
Arena Pharmaceuticals$806.43 million5.00$397.55 million$7.698.69

Arena Pharmaceuticals has higher revenue and earnings than Nkarta.

Profitability

This table compares Nkarta and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NkartaN/AN/AN/A
Arena PharmaceuticalsN/A-33.17%-30.41%

Institutional and Insider Ownership

77.1% of Nkarta shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 3.1% of Arena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Nkarta and Arena Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nkarta00503.00
Arena Pharmaceuticals001503.00

Nkarta currently has a consensus price target of $59.00, suggesting a potential upside of 64.90%. Arena Pharmaceuticals has a consensus price target of $92.80, suggesting a potential upside of 38.90%. Given Nkarta's higher possible upside, research analysts plainly believe Nkarta is more favorable than Arena Pharmaceuticals.

Summary

Arena Pharmaceuticals beats Nkarta on 4 of the 7 factors compared between the two stocks.

Nkarta (NASDAQ:NKTX) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, profitability, earnings, institutional ownership and dividends.

Institutional & Insider Ownership

77.1% of Nkarta shares are held by institutional investors. Comparatively, 92.9% of Agios Pharmaceuticals shares are held by institutional investors. 3.2% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Nkarta and Agios Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NkartaN/AN/AN/A
Agios Pharmaceuticals-170.65%-57.63%-37.15%

Earnings & Valuation

This table compares Nkarta and Agios Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NkartaN/AN/AN/AN/AN/A
Agios Pharmaceuticals$117.91 million32.68$-411,470,000.00($6.86)-8.05

Nkarta has higher earnings, but lower revenue than Agios Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and price targets for Nkarta and Agios Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nkarta00503.00
Agios Pharmaceuticals03702.70

Nkarta currently has a consensus target price of $59.00, suggesting a potential upside of 64.90%. Agios Pharmaceuticals has a consensus target price of $64.6364, suggesting a potential upside of 17.12%. Given Nkarta's stronger consensus rating and higher possible upside, equities analysts clearly believe Nkarta is more favorable than Agios Pharmaceuticals.

Summary

Nkarta beats Agios Pharmaceuticals on 5 of the 9 factors compared between the two stocks.


Nkarta Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$75.21+0.2%$4.67 billionN/A-6.13Analyst Report
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$74.72+0.5%$4.36 billion$6.87 million-7.22Analyst Report
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.75+0.3%$4.33 billion$204.89 million-37.19
I-Mab logo
IMAB
I-Mab
1.2$58.42+4.3%$4.20 billion$4.31 million-2.02News Coverage
Gap Down
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$66.81+1.4%$4.03 billion$806.43 million-9.46Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.19+0.1%$3.85 billion$117.91 million-11.19Upcoming Earnings
Insider Selling
LEGN
Legend Biotech
1.2$28.28+3.6%$3.76 billion$64.39 million0.00Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.07+0.2%$3.70 billionN/A-6.21Upcoming Earnings
Analyst Report
Insider Selling
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$20.10+1.8%$3.66 billion$114.62 million-8.10
Insmed logo
INSM
Insmed
1.2$35.02+3.5%$3.62 billion$136.47 million-13.47Upcoming Earnings
News Coverage
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$73.31+0.1%$3.60 billionN/A-20.89
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$63.12+4.6%$3.38 billion$1.11 billion20.30Upcoming Earnings
High Trading Volume
News Coverage
Gap Up
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$20.87+2.9%$3.34 billion$339.08 million-12.13Analyst Revision
News Coverage
Alkermes logo
ALKS
Alkermes
1.2$20.92+2.0%$3.33 billion$1.17 billion-45.48Upcoming Earnings
Insider Selling
Analyst Revision
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$91.51+0.8%$3.31 billion$26.52 million-8.06Unusual Options Activity
News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$46.82+1.8%$3.29 billion$306.98 million-6.70
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$39.76+2.4%$3.29 billionN/A0.00News Coverage
Arvinas logo
ARVN
Arvinas
1.7$66.26+0.8%$3.24 billion$42.98 million-25.88Upcoming Earnings
Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$46.26+0.4%$3.23 billion$36.13 million-69.04News Coverage
MorphoSys logo
MOR
MorphoSys
0.3$23.18+1.6%$3.05 billion$80.43 million110.39
OPKO Health logo
OPK
OPKO Health
1.9$4.37+0.7%$2.93 billion$901.90 million-24.28News Coverage
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$107.45+0.8%$2.90 billionN/A-53.46
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
0.9$75.39+1.7%$2.88 billion$644.77 million-10.75News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$64.45+1.0%$2.83 billion$421.03 million22.69News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.88+2.9%$2.80 billion$306.49 million26.83
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$44.50+2.9%$2.75 billionN/A-24.45
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$47.53+3.2%$2.74 billion$25 million-9.51Insider Selling
Analyst Revision
News Coverage
Organogenesis logo
ORGO
Organogenesis
1.0$21.33+0.4%$2.73 billion$260.98 million-355.50News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$43.16+2.0%$2.68 billion$2.11 million-9.34Analyst Report
Unusual Options Activity
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.87+1.0%$2.61 billion$182.24 million-8.58Analyst Upgrade
Insider Selling
Xencor logo
XNCR
Xencor
1.0$44.44+4.9%$2.58 billion$156.70 million-31.74
ALX Oncology logo
ALXO
ALX Oncology
1.9$62.66+7.4%$2.51 billionN/A0.00Insider Selling
News Coverage
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$30.42+3.7%$2.46 billion$60,000.00-9.45Analyst Revision
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.8$34.70+2.2%$2.46 billion$15 million-18.17News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$147.98+2.8%$2.46 billion$120.28 million-149.47Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.7$53.01+1.5%$2.42 billion$33.94 million-91.40
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$55.85+2.3%$2.29 billionN/A0.00Analyst Report
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$45.81+0.0%$2.28 billion$963.01 million14.23
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
2.0$28.86+1.8%$2.20 billion$23.90 million-17.93Analyst Report
Insider Selling
Analyst Revision
News Coverage
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$27.06+0.8%$2.08 billion$103.54 million-20.35
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$129.29+0.7%$2.07 billionN/A-11.68
Amarin logo
AMRN
Amarin
1.6$5.19+1.9%$2.04 billion$429.76 million-103.78Upcoming Earnings
MacroGenics logo
MGNX
MacroGenics
1.2$33.66+0.1%$2.02 billion$64.19 million-10.75Upcoming Earnings
Analyst Report
Insider Selling
Unusual Options Activity
News Coverage
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$27.80+1.1%$1.98 billion$410,000.00-6.04
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$52.87+3.3%$1.98 billionN/A-19.65Unusual Options Activity
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$61.37+4.4%$1.96 billionN/A-26.11
FibroGen logo
FGEN
FibroGen
1.8$21.12+0.3%$1.94 billion$256.58 million-8.09
Generation Bio logo
GBIO
Generation Bio
1.6$34.29+8.0%$1.93 billionN/A0.00
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.70+1.0%$1.90 billion$34.51 million-17.69
Kura Oncology logo
KURA
Kura Oncology
1.6$28.45+1.1%$1.88 billionN/A-17.45News Coverage
This page was last updated on 4/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.